Cx-611

N/A

Report date: 2025/07/07 20:00:09

Base Information

Drug NameCx-611

Drug Alias NameeASC - TiGenixAdipose-derived allogenic stem cell therapy - TiGenix NVCx-611

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Adipose-derived

Mechanisms of ActionCell replacementsImmunomodulatorsInflammation mediator inhibitors +[4]

TargetsNot applicable

Therapy Area/IndicationsSepsisPneumonia, Bacterial

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumNetherlandsNorway +[7]

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesTigenix Nv

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesTigenix Sau

Active IndicationsN/A

Inactive IndicationsSepsisPneumonia, Bacterial

Other Information

ATC CodeN/A